Medtronic unveils mobile teaching labs; ReShape snags $15.8M for gastric balloon;

 @FierceMedDev: Roche Dx is slashing jobs as it rethinks its diabetes business. More | Follow @FierceMedDev

 @MarkHFierce: Scientists can produce stem cells in great numbers from cadaver scalp tissue. More | Follow @MarkHFierce

 @DamianFierce: Japan's Sysmex is in talks to buy Dune Medical Devices for $200M, according to a report. More | Follow @DamianFierce

> NinePoint Medical, a 2012 Fierce 15 winner, is touting new data demonstrating its NvisionVLE imaging system to be more effective than standard biopsy protocol. News

> Medtronic ($MDT) is unveiling a fleet of mobile labs that will trek across the country to educate surgeons on how to use the company's spinal technologies. More

> Spinal Restoration has closed a $5 million financing round, planning to use the money to commercialize its Biostat pain management system. Release

> Here's something to add to the list of stenting benefits: Patients who receive percutaneous coronary intervention report improved sex lives. Story

> CardioDx, another Fierce 15 acolyte, cites a new study showing the company's Corus CAD diagnostic is more cost-effective than imaging for patients who may have coronary artery disease. Item

> ReShape Medical pulled in $15.8 million to commercialize anti-obesity gastric balloon. Article

> Japan's Sysmex snagged 510(k) clearance for its XN series of blood hematology analyzers. News

> Boston Scientific ($BSX) is announcing positive results for its Promus drug-eluting stent among patients with long vascular lesions. More

> Researchers have developed a new adhesive paper that could make for low-cost diagnostics available in the developing world. Story

Biotech News

 @FierceBiotech: Hirano bodies may block Alzheimer's-related cell death. More | Follow @FierceBiotech

 @JohnCFierce: So AstraZeneca and Ironwood are getting close. AZ pays $25M in cash, up to $125M in miles for China rights to linaclotide; sharing revenue. | Follow @JohnCFierce

 @RyanMFierce: e-Therapeutics (computer-enabled network pharmacology) has shelved a MRSA candidate to focus on cancer program. More (reg. req.) | Follow @RyanMFierce

> Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact. Report

> GSK taps stem cell discovery to spot heart threats early. Story

> Celgene wraps promising PhIII data on new multiple myeloma challenger. Article

Pharma News

@FiercePharma: EMA says it's investigating Roche for possible shortcomings in pharmacovigilance. More | Follow @FiercePharma

> Eisai snags FDA nod for blockbuster hopeful Fycompa. Story

> Roche to shed 100 jobs in diabetes Dx revamp. Item

> Judge orders FDA to let Watson sell generic Actos. Article

Biotech Research News

> Australian scientists grow HIV antibodies in cow's milk. More

> A transplant anti-rejection treatment could be the next cancer drug. Article

> Pluristem's placental stem cells combat fibrosis in preclinical test. Story

> Scientists produced stem cells from cadaver scalp tissue. Item

Pharma Manufacturing News

> China's WuXi AppTec opens biologics plant. More

> Mexico's Neolpharma snags Pfizer Puerto Rico plant. News

> Mylan buying vertically integrated SMS oncology plant. Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.